Dr Reeves is giving evidence about his treatment of our daughter Shakaya in 2019…..when he discovered leaking of the artificial heart valve. His records states she needed heart surgery urgently to repair the heart valve ❤️
Iron ore futures fell by US16 cents or 0.1% to US$106.63 a tonne as traders weighed curbs in electricity consumption in China's Sichuan province that hit steel production.
#ausbiz#ausecon#commsec
Corporate Travel Management $CTD FY22 results:
-Total transaction value +215% to $5.1bn
-Revenue +94% to $389m
-Underlying EBITDA of $59.8m (FY21: $7.2m loss)
-Underlying profit of $17.5m (FY21: $32.3m loss)
-Corporate cash +36% to $126.5m
-Final div of 5cps (1st div since 2019)
A NSW police officer charged with assaulting an Indigenous teenager during an arrest justified a "leg sweep" on the 16-year-old because he thought he was about to be assaulted, a Sydney court has heard.
https://t.co/4mEly0qpcy
Redbubble $RBL FY22 results:
-Underlying marketplace revenue -3% to $472.2m
-Gross profit -18% to $183.1m
-Net loss of $24.6m (FY21: Net profit of $31.2m)
-Cash at bank -10% to $89.1m
-'Delivery time estimates reduced 1-5 days'
-Avg. base price rise of ~6% implemented in May
Bapcor $BAP FY22 result:
-Rev +4.6% to $1.8bn
-Underlying profit +1.2% to $131.6m, 'in line with market guidance'
-Final div +4.5% to 11.5cps
-'Supply chains were and continue to be disrupted globally' with 'ordering lead times' at 'unprecedented levels'
-Net debt of $262m
Dexus $DXS FY22 results:
-NPAT +41.9% to $1,615.9m. Driven partly by 'gains on investment properties'
-Underlying funds from operations +10.1% to $734.2m
-Anticipate a 'challenging period over the next 2 years'
-Expects FY23 distribution of 50-51.5cps (FY22: 53.2cps)
Super Retail Group $SUL FY22 results:
-Total sales +2.8% to $3.55bn, 'driven by a strong second half performance'
-Online sales +44% to $601m
-Gross margin -1.2% to 46.8%
-Normalised NPAT -20% to $244.1m. Margins -1.9% to 6.8%
-FY23 like-for-like sales growth +17% as at wk 6
Magellan Financial Group $MFG FY22 results:
-Revenue -23% to $554m
-Profit +44% to $383m, 'largely attributed to the material one-off after tax expense' (~$148m) recognised in FY21
-Average FUM over FY22 of $94.3bn. Closing FY22 FUM of $61.3bn
-Final div -37% to 65cps
$CSL FY22 results:
- Sales +2% to US$10.1bn
- Immunoglobulin sales limited by constrained plasma collections in 2021, although improved 2H performance 'reflects growth in plasma collected'
- Net profit -5% to US$2.25bn
- Final dividend US$1.18/s
$CBA trades ex-dividend on Wednesday for its $2.10 per share final dividend, which is payable on Sep 29. $CBA is the second largest stock on the #ASX behind just $BHP with a market cap of ~$172bn.